EVOK - Evoke to get US patent for nasal spray Gimoti
- Evoke Pharma ( NASDAQ: EVOK ) said it will get a get patent from the U.S. Patent and Trademark Office (USPTO) for its nasal spray Gimoti.
- Gimoti is a nasal spray formulation of metoclopramide for relief of symptoms linked with acute and recurrent diabetic gastroparesis, a condition in which stomach takes too long to empty, the company said in a Sept. 20 press release.
- When granted, the patent will cover methods for treating moderate-to-severe gastroparesis with metoclopramide with an intranasal route of administration, Evoke noted.
- The company added that the patent will expire in 2037.
For further details see:
Evoke to get US patent for nasal spray Gimoti